Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar



Article History
Submitted: 29 Jan 2016
Revised: 16 Mar 2016
Accepted: 02 Apr 2016
First published online: 29 Jun 2016

Article Access Statistics
Abstract Page Views: 372
PDF Downloads: 219
Full Text Views: 0

Adv Pharm Bull. 2016;6(2):171-177 doi: 10.15171/apb.2016.024

Silencing of High Mobility Group Isoform I-C (HMGI-C) Enhances Paclitaxel Chemosensitivity in Breast Adenocarcinoma Cells (MDA-MB-468)

Research Article

Behzad Mansoori 1,2, Ali Mohammadi 1, Samira Goldar 1, Dariush shanehbandi 1, Leila Mohammadnejad 1, Elham Baghbani 1, Tohid Kazemi 1, Saeed Kachalaki 1, Behzad Baradaran 1 *

1 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.



Abstract

Purpose: HMGI-C (High Mobility Group protein Isoform I-C) protein is a member of the high-mobility group AT-hook (HMGA) family of small non-histone chromosomal protein that can modulate transcription of an ample number of genes. Genome-wide studies revealed up regulation of the HMGI-C gene in many human cancers. We suggested that HMGI-C might play a critical role in the progression and migration of various tumors. However, the exact role of HMGI-C in breast adenocarcinoma has not been cleared.

Methods: The cells were transfected with siRNAs using transfection reagent. Relative HMGI-C mRNA and protein levels were measured by quantitative real-time PCR and Western blotting, respectively. The cytotoxic effects of HMGI-C siRNA, Paclitaxel alone and combination on breast adenocarcinoma cells were determined using MTT assay. The migration after treatment by HMGI-C siRNA, Paclitaxel alone and combination were detected by wound-healing respectively.

Results: HMGI-C siRNA significantly reduced both mRNA and protein expression levels in a 48 hours after transfection and dose dependent manner. We observed that the knockdown of HMGI-C led to the significant reduced cell viability and inhibited cells migration in MDA-MB-468 cells in vitro.

Conclusion: These results propose that HMGI-C silencing and Paclitaxel treatment alone can inhibit the proliferation and migration significantly, furthermore, synergic effect of HMGI-C siRNA and Paclitaxel showed higher inhibition compared to mono treatment. Taken together, HMGI-C could be used as a promising therapeutic agent in the treatment of human breast adenocarcinoma. Therefore HMGI-C siRNA may be an effective adjuvant in human breast adenocarcinoma.







Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Mansoori B
Articles by Mohammadi A
Articles by Goldar S
Articles by shanehbandi D
Articles by Mohammadnejad L
Articles by Baghbani E
Articles by Kazemi T
Articles by Kachalaki S
Articles by Baradaran B

PubMed
Articles by Mansoori B
Articles by Mohammadi A
Articles by Goldar S
Articles by shanehbandi D
Articles by Mohammadnejad L
Articles by Baghbani E
Articles by Kazemi T
Articles by Kachalaki S
Articles by Baradaran B



Share this article!

Press Manuscript Online. Powered by MAADRAYAN